This week, we round out our discussion on the early stage breast cancer, turning our attention to the triple negative subtype. Once again, there are a lot of trials and data, but be sure to check out the show notes for the highlights! Content: - What is TNBC?-What is the data to support the use of neoadjuvant therapy in this disease? - What is "pathologic CR" and how is different than "residual cancer burden"?- Can we ever omit neoadjuvant therapy?- What are our options for chemotherapy regimens in neoadjuvant and adjuvant setting? ** This episode has been sponsored by HemOnc.org** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related